Carlyle Presents at Morgan Stanley Conference, Reiterates Growth Narrative Amid Persistent Earnings Quality Concerns

What happened

Carlyle Group management presented at the Morgan Stanley US Financials Conference on June 10, 2026, likely reiterating its strategy to shift toward credit, secondaries, and insurance-driven fee income. While the firm has achieved record fee-related earnings and expanded AUM to $474 billion, the DeepValue report flags that GAAP net income remains volatile, realized carry was just $19 million in Q3 2025, and pending fee-earning AUM declined 9% year-over-year. The stock at ~$59 already prices in mid-teens FRE growth, leaving limited upside versus a base-case value of $60. Management's updated 2025 FRE growth target of 'at least 10%' raises execution risk, especially with the politically sensitive Lukoil deal pending OFAC approval. Under the surface, earnings quality is fragile—concentrated accrued carry, CLO leverage, and a weak buyout exit pipeline mean the optimistic conference messaging masks structural headwinds.

Implication

Today's presentation offers no incremental reason to alter the WAIT rating. Management's narrative of platform diversification is well-known and already reflected in multiples. Near-term, the stock lacks a margin of safety: valuation at ~32x trailing GAAP P/E and 4.7x net debt/EBITDA leaves little room for error. The key catalysts to watch are Q4 2025 FRE delivery (must meet 'at least 10%' growth), OFAC's decision on the Lukoil deal by end-February 2026, and a sustained rebound in realized performance revenues above $100 million per quarter. Until these milestones provide tangible evidence that the shift to credit/solutions is translating into higher-quality, less volatile earnings, the risk/reward favors waiting for a pullback toward $50 or clearer execution proof.

Thesis delta

No material shift in thesis from the conference. The core investment case remains unchanged: Carlyle's transition to a more recurring-fee platform is underway but the stock's valuation already embeds optimistic assumptions. The WAIT rating persists, with attractive entry near $50 and upside re-assessment only after sustained 12%+ FRE growth and normalized carry realization.